Format

Send to

Choose Destination
Cancer Cell. 2002 Jun;1(5):413-5.

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

Author information

1
Department of Medicine, Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles 90095, USA. csawyers@mednet.ucla.edu

Abstract

Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway.

PMID:
12124170
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center